NIHON TRIM (6788) FY2026 Q3 Earnings Report

Quick View

Executive Summary

For the cumulative Q3 period of the fiscal year ending March 2026, the Company reported a mixed result characterized by higher revenue but declines in Operating Income, Ordinary Income, and Net Income. Revenue increased to ¥18.34B (+8.1% YoY), while Operating Income was ¥2.28B (down 14.6% YoY), Ordinary Income was ¥2.42B (down 15.2% YoY), and Net Income attributable to owners of the parent was ¥1.56B (down 16.2% YoY). The primary reason that revenue growth did not translate into profit growth was that the combined increase in the cost of sales and selling, general and administrative expenses outpaced revenue growth.

Factors Affecting Performance

【Revenue】Revenue increased to ¥18.34B, up +8.1% YoY (+¥1.35B). Both segments secured revenue growth: the core Water Healthcare Business generated ¥16.03B (+8.2% YoY, 87.4% of total revenue), while the Medical-Related Business generated ¥2.32B (+7.4% YoY, 12.6% of total revenue).

【Profit and Loss】Operating Income was ¥2.28B (down 14.6% YoY). Although the gross profit margin was maintained at 68.2%, the SG&A expense ratio rose to 55.7%, putting pressure on profit. The profit margin of the Water Healthcare Business declined from approximately 15.9% to 13.0%, while that of the Medical-Related Business fell from approximately 14.3% to 8.7%; both businesses therefore recorded higher revenue but lower profit. Ordinary Income was ¥2.42B (down 15.2% YoY), as non-operating income and expenses were broadly in line with the previous year, while Net Income was ¥1.56B (down 16.2% YoY) after tax expenses. Extraordinary income and expenses were minor, consisting only of a ¥0.03B gain on the sale of fixed assets. The earnings structure therefore reflects deterioration in recurring operating profitability. In conclusion, the Company as a whole recorded higher revenue but lower profit.

Segment Analysis

The Water Healthcare Business generated revenue of ¥16.03B (+8.2% YoY) and Operating Income of ¥2.08B (down 12.0% YoY), with a profit margin of 13.0% (down from approximately 15.9% in the previous year). Although it is the core business, accounting for 87.4% of consolidated revenue, its profit margin deteriorated. The Medical-Related Business generated revenue of ¥2.32B (+7.4% YoY) and Operating Income of ¥0.20B (down 34.5% YoY), with a profit margin of 8.7% (a significant decline from approximately 14.3% in the previous year). The extent of margin deterioration was greater than in the core business. Both businesses secured revenue growth while experiencing lower profit margins, and the decline in the Company-wide Operating Income margin—from 15.7% in the previous year to 12.4% in the current period, a decrease of approximately 331bp—was attributable to deteriorating profitability in both segments.

Key Financial Metrics

【Profitability】The Operating Income margin was 12.4%, down approximately 331bp from approximately 15.7% in the same period of the previous year, while the Net Income margin remained at approximately 8.5%. The gross profit margin remained high at 68.2%; the decline in profitability reflects the Company’s inability to fully offset rising costs through price pass-through and product mix improvements.【Cash Quality】Trade receivables were ¥7.00B, representing 20.1% of total assets. DSO was approximately 104 days and CCC was approximately 149 days, indicating a structure that requires considerable time for cash collection.【Investment Efficiency】ROE was 6.8%, total asset turnover was 0.526x, and financial leverage was approximately 1.41x. The Company’s substantial equity and cash holdings are relatively depressing capital efficiency.【Financial Soundness】The Equity Ratio was 71.1%, the current ratio was approximately 312.9%, and interest-bearing debt consisted solely of ¥1.05B in long-term borrowings, equivalent to 4.2% of net assets. The financial foundation is therefore highly conservative and stable.

Cash Flow Analysis

Although detailed disclosure of the cash flow statement is unavailable, changes in the balance sheet provide insight into fund movements. Cash and deposits were ¥13.93B, down from ¥15.39B in the same period of the previous year, but remained high at approximately 39.9% of total assets. Trade receivables increased to ¥7.00B from ¥6.34B in the same period of the previous year, suggesting that working capital expanded in line with revenue growth. Accounts payable remained small at ¥0.66B, limiting the cash flow benefit from trade payables. Advances received were ¥4.36B, representing approximately 59.9% of current liabilities; business operations involving customer prepayments are influencing the funding structure. Interest-bearing debt was limited to ¥1.05B in long-term borrowings, indicating a low dependence on financing through financial activities. Overall, amid revenue growth, the increase in trade receivables may have contributed to the stagnation in the cash balance.

Quality of Earnings

Current-period profit was largely unaffected by extraordinary income and expenses and was based on recurring operating earnings. Extraordinary income consisted solely of a ¥0.03B gain on the sale of fixed assets, while extraordinary losses were limited to a ¥0.002B loss on the disposal of fixed assets; their impact on Profit Before Tax of ¥2.42B was minor. Non-operating income was ¥0.19B, or approximately 1.0% of revenue, while non-operating expenses were also small at ¥0.04B, with an insignificant interest burden. Accordingly, the gap between Profit Before Tax and Net Income was primarily attributable to corporate income taxes and other tax expenses, with an effective tax rate of approximately 30.4%. No inflation or suppression of profit through non-recurring items was observed. However, the increasing trend in trade receivables, with DSO of approximately 104 days, warrants confirmation of future cash conversion and suggests that a certain divergence may exist between accrual-based earnings and actual cash flow.

Earnings Forecast and Guidance

The full-year company forecasts are revenue of ¥25.00B (+11.3% YoY), Operating Income of ¥3.54B (+7.7% YoY), and Ordinary Income of ¥3.70B (+4.7% YoY). The Q3 cumulative progress rates are 73.4% for revenue, 64.4% for Operating Income, and 65.5% for Ordinary Income. Revenue progress is only 1.6pt below the standard 75%, but the progress rates for Operating Income and Ordinary Income are approximately 10pt below the standard, indicating a notable delay on the profit front. To achieve the full-year plan, approximately ¥6.66B in revenue and approximately ¥1.26B in Operating Income are required in Q4. This corresponds to an Operating Income margin of approximately 18.9% in Q4, substantially above the Q3 cumulative margin of 12.4%. Accordingly, achieving the full-year profit plan requires a marked improvement in the Q4 profit margin.

Shareholder Returns

The Q2 dividend was ¥0 per share, while the full-year dividend forecast is ¥130 per share. Based on forecast EPS of ¥304.74, the forecast Payout Ratio is approximately 42.7%, below the 60% level generally regarded as a benchmark for sustainability. However, the full-year progress rate for cumulative Q3 Net Income attributable to owners of the parent was 67.8%, below the standard 75%, meaning that achievement of the dividend forecast depends on a recovery in profit in the second half. The financial foundation—cash and deposits of ¥13.93B, a current ratio of approximately 312.9%, and low interest-bearing debt—supports the Company’s capacity to fund dividends.

Risk Factors

1. Declining profitability in the core business: The Water Healthcare Business accounts for 87.4% of consolidated revenue and is the core business; however, against revenue growth of +8.2%, Operating Income declined by 12.0% and the profit margin fell by approximately 298bp. Deterioration in the profitability of the core business would have a significant impact on company-wide earnings.

2. Deteriorating working capital efficiency: DSO was approximately 104 days and CCC was approximately 149 days, exceeding general cautionary thresholds of approximately 60 days for DSO and 120 days for CCC. As revenue continues to grow, expansion in trade receivables may place pressure on cash efficiency.

3. Deteriorating profitability in the Medical-Related Business: Against revenue growth of +7.4%, Operating Income declined by 34.5% and the profit margin fell by approximately 558bp, representing a more pronounced deterioration than in the core business. Commercialization of research and development, regulatory compliance, and changes in the competitive environment may become factors affecting earnings volatility.

Industry Benchmarks (Reference; Compiled by the Company)

Industry Benchmarks (manufacturing)

Profitability and Return

The Company’s Operating Income margin and Net Income margin both exceed the industry median, placing its profitability level relatively high within the industry.

Growth and Capital Efficiency

The Revenue growth rate significantly exceeds the industry median, demonstrating growth that ranks among the higher levels within the industry.

※Source: Compiled by the Company

Key Takeaways from the Earnings Results

1. Revenue growth continued in both segments, but the Operating Income margin declined by approximately 331bp YoY, making the inability to translate revenue growth into profit growth a structural characteristic of the current fiscal period.

2. Progress against the full-year plan diverged, with revenue at 73.4% versus Operating Income at 64.4%; an Operating Income margin of approximately 18.9% will be required in Q4. The trend in second-half margin recovery will be key to achieving the full-year plan.

3. While the Company has a strong financial foundation, including an Equity Ratio of 71.1% and a current ratio of approximately 312.9%, working capital efficiency indicators of approximately 104 days for DSO and approximately 149 days for CCC should be monitored as indicators of cash collection during a period of revenue growth.

Theoretical Share Price (Reference Value)

Sensitivity: ¥3,104–¥3,283 at ±1% for the cost of equity, and ¥3,190–¥3,194 at ±0.1 for ω.

Notes:

• Net assets as of the end of the quarter are used (there is a timing difference from the full-year forecast).

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not forecast or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting with professionals as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2026 Q3 performance was mixed: revenue growth remained solid, but profit conversion weakened materially and left the company behind its full-year operating-profit pacing. Cumulative Q3 revenue rose 8.1% year on year to ¥18.35bn. Operating income fell 14.6% to ¥2.28bn, while ordinary income declined 15.2% to ¥2.43bn. Profit attributable to owners of parent declined 16.2% to ¥1.56bn, equivalent to EPS of ¥206.29. Gross profit increased 6.7% to ¥12.51bn, but lagged sales growth. Consequently, gross margin contracted by approximately 90bp year on year to 68.2% from 69.4%. SG&A expense increased 12.3% to ¥10.23bn, substantially faster than revenue growth. This drove operating margin down by approximately 330bp to 12.4% from 15.7%. The Water Healthcare segment remained the core business, contributing 87.4% of revenue and 91.1% of segment profit. Its sales increased 8.2%, but segment profit declined 12.0%, indicating that the consolidated margin pressure was concentrated mainly in the largest business. Medical-related sales grew 7.4%, but segment profit fell 34.5% and its margin compressed sharply. The decline in profit before tax was larger than the ordinary-income decline because the prior-year comparison included a gain on sale of investment securities. The current period contained only immaterial extraordinary items, supporting the view that reported Q3 earnings are principally recurring despite lower profitability. The balance sheet is highly liquid, with cash and deposits of ¥13.93bn and a current ratio of 312.9%. Debt is modest at ¥1.05bn of long-term loans, while debt/capital is only 4.1%. However, receivable collection efficiency is a material operating concern, with DSO of 104 days and an annualized cash conversion cycle of 149 days. Management's full-year sales target remains broadly achievable at the current run-rate, but operating-income progress of 64.4% versus the normal 75% Q3 benchmark requires a meaningful Q4 margin recovery. The full-year dividend forecast of ¥130 per share implies a manageable dividend payout ratio of approximately 42.7% based on forecast EPS of ¥304.74. The principal issue for investors is therefore not solvency, but whether sales growth can again translate into segment-level margin expansion and improved working-capital discipline.

Profitability Analysis

Reported annualized ROE is 8.4%, derived through the provided DuPont framework as an 8.5% net profit margin × 0.701x asset turnover × 1.41x financial leverage. The largest adverse change is margin rather than leverage: operating margin declined about 330bp year on year to 12.4%, despite still being within the stated 8-15% good profitability range. Gross margin declined about 90bp to 68.2%, showing some pressure at the gross-profit level. More importantly, SG&A increased 12.3% versus revenue growth of 8.1%, creating negative operating leverage and accounting for the larger operating-margin decline. The Water Healthcare business is the core profit engine, generating ¥2.08bn of segment profit on ¥16.03bn of sales, for a 13.0% segment margin versus 16.0% a year earlier. Medical-related operations generated ¥0.20bn of segment profit on ¥2.32bn of sales, for an 8.7% margin versus 14.3% previously; this was the largest segment-level margin compression. Financial leverage is restrained and does not appear to be the source of ROE risk. The 5-factor DuPont tax burden was 0.643, consistent with the 30.4% effective tax rate, while the interest burden of 1.063 reflects net non-operating income rather than financing stress. Interest expense was only ¥4m and interest coverage was 582.82x. Annualized ROA, calculated using annualized cumulative Q3 profit attributable to owners and average total assets, is approximately 5.9%, which is adequate but below the company's margin-rich business model's potential. The current 8.4% ROE is slightly above the stated 8% concern threshold but remains below the 10-15% benchmark for good returns. Improvement depends primarily on restoring SG&A efficiency and segment margins rather than increasing balance-sheet leverage.

Growth Assessment

Revenue growth was broad-based across both reported segments. Water Healthcare revenue increased by ¥1.22bn to ¥16.03bn, while Medical-related revenue increased by ¥0.16bn to ¥2.32bn. The growth profile is therefore led by the established water purifier and related Water Healthcare operations, rather than by a disproportionate contribution from the smaller medical business. Revenue quality is supported by the absence of material segment eliminations and by the fact that growth was recorded in both external-revenue streams. Nevertheless, profit quality of growth deteriorated because consolidated operating income declined ¥0.39bn despite the ¥1.37bn revenue increase. The Medical-related segment's ¥0.11bn profit decline is particularly important because it suggests that its incremental revenue generated materially weaker contribution than in the prior year. The full-year revenue forecast is ¥25.00bn, and Q3 cumulative revenue represents 73.4% of that target, only 1.6 percentage points below the standard 75% Q3 progress rate. This makes the sales target broadly consistent with the existing trajectory. Q3 operating income represents 64.4% of the ¥3.54bn full-year forecast, 10.6 percentage points below the standard 75% pace. Ordinary-income progress is 65.5% against the ¥3.70bn target, also below normal Q3 pacing. Profit attributable to owners has reached 67.8% of the ¥2.30bn forecast, requiring a stronger final quarter than implied by the year-to-date margin trend. Achieving guidance therefore requires a Q4 operating-income contribution of about ¥1.26bn, compared with ¥2.28bn generated across the first nine months. The outlook hinges on recovery in Water Healthcare selling efficiency and stabilization of the Medical-related segment margin.

Financial Health

Financial health is strong. Current assets of ¥22.77bn exceeded current liabilities of ¥7.28bn by ¥15.49bn, producing working capital of ¥15.49bn and a current ratio of 312.9%. The quick ratio was also 312.9%, reflecting substantial immediately liquid assets rather than inventory-dependent liquidity. Cash and deposits of ¥13.93bn alone were almost 1.9x current liabilities. Total liabilities were ¥10.08bn against total equity of ¥24.82bn, with equity funding 71.1% of total assets. Long-term loans were only ¥1.05bn, or 3.0% of total assets, and debt/capital was a conservative 4.1%. The reported debt-to-equity ratio was 0.41x and remains well below the 2.0x level that would indicate aggressive leverage. There is no apparent short-term debt maturity mismatch: current assets significantly exceed current liabilities, while disclosed interest-bearing debt consists of long-term loans. Interest servicing capacity is exceptionally strong, as shown by 582.82x interest coverage. Investment securities increased by ¥1.07bn, or 81.7%, to ¥2.37bn and now represent 6.8% of total assets; this increases exposure to market-value movements and portfolio allocation decisions. Treasury stock increased by ¥1.09bn, or 31.9%, to negative ¥4.49bn, equal to 12.9% of total assets; the capital action reduces outstanding equity capital and can support per-share metrics, but reduces liquidity available for other uses. Goodwill was only ¥0.28bn, or 1.1% of equity, and intangible assets were 1.7% of assets, leaving balance-sheet valuation and M&A impairment risk low. Defined-benefit liability of ¥0.39bn, directors' retirement provision of ¥0.29bn, and bonus provision of ¥0.08bn are manageable relative to equity and liquidity.

Notable B/S Changes

Investment securities: +¥1.07bn (+81.7%) to ¥2.37bn — portfolio exposure increased materially and should be monitored for valuation volatility and capital-allocation rationale. Treasury stock: -¥1.09bn (-31.9%) to -¥4.49bn — indicates a material increase in treasury-share holdings; it may support per-share capital efficiency but uses capital that could otherwise support investment, dividends, or liquidity.

Cash Flow Quality

Cash-flow quality cannot be assessed directly because operating cash flow, investing cash flow, financing cash flow, capital expenditure and free cash flow figures are not provided. Accordingly, no OCF/net-income ratio, cash conversion ratio, free-cash-flow calculation, or dividend cash-coverage calculation is presented. Balance-sheet working-capital indicators nevertheless identify a material cash-conversion risk. The quality alert for annualized DSO of 104 days is significant because it exceeds the 60-day warning level and means a large share of reported revenue remains tied up in receivables. Trade receivables increased 10.3% year on year to ¥7.00bn, faster than 8.1% revenue growth, which is consistent with slower cash collection or a less favorable sales-collection mix. The quality alert for an annualized 149-day cash conversion cycle is also significant because it is well above the 120-day warning threshold. A long cash conversion cycle increases funding needs even though the company currently has ample cash. Finished goods declined 7.0% to ¥0.58bn and raw materials declined 6.7% to ¥1.03bn, so the working-capital concern is more concentrated in customer receivables than in inventory accumulation. Advances received increased 7.0% to ¥4.36bn, providing a partial offset within current liabilities. Management should demonstrate that the elevated DSO reflects contractual billing timing or customer mix rather than deterioration in collection discipline. The balance-sheet cash position currently absorbs this risk, but sustained receivable expansion would weaken the conversion of accounting earnings into cash.

Dividend Sustainability

The full-year dividend forecast is ¥130 per share. Based on forecast EPS of ¥304.74, the prospective dividend payout ratio is approximately 42.7%, below the 60% sustainability benchmark. This indicates that the dividend is covered by forecast accounting earnings with a reasonable retention buffer. Q3 EPS of ¥206.29 has reached 67.7% of forecast EPS, broadly consistent with the 67.8% progress rate for profit attributable to owners. The company has substantial balance-sheet capacity, including ¥13.93bn of cash and deposits, modest long-term loans of ¥1.05bn, and a 312.9% current ratio. These factors support near-term dividend resilience even if the Q4 earnings recovery is less robust than planned. Treasury stock rose by ¥1.09bn year on year, indicating meaningful capital allocation toward share repurchases or treasury-share acquisition. Because the cash amount of purchases and dividend cash payments is not provided, a total return ratio cannot be calculated. Dividend sustainability should therefore be assessed primarily against the 42.7% forecast dividend payout ratio and the company's strong liquidity, while monitoring whether buybacks remain material alongside dividends.

Risk Assessment

Business risks include Margin-execution risk: consolidated operating margin declined approximately 330bp to 12.4% as SG&A rose 12.3%, faster than 8.1% sales growth., Core-business risk: Water Healthcare represents 87.4% of sales and 91.1% of segment profit, so its segment-margin decline from 16.0% to 13.0% has a disproportionate effect on group earnings., Medical-related profitability risk: segment profit declined 34.5% despite 7.4% revenue growth, reducing margin to 8.7% from 14.3%., Industry-specific manufacturing and consumer-durable risk: demand for water-healthcare equipment and related products can be sensitive to discretionary consumer spending, channel productivity, product competition, and sales-force efficiency., Receivable-collection risk: annualized DSO of 104 days exceeds the 60-day warning level, potentially signalling extended customer terms, delayed collection, or a less favorable sales mix., Cash-conversion risk: the annualized 149-day cash conversion cycle exceeds the 120-day warning threshold and can constrain the cash benefit of revenue growth..

Financial risks include Investment-portfolio exposure increased as investment securities rose 81.7% year on year to ¥2.37bn; valuation changes can affect comprehensive income and capital allocation flexibility., Capital-allocation risk is elevated modestly by the ¥1.09bn increase in treasury stock, particularly if future buybacks coincide with weaker profit conversion., Comprehensive income declined 23.8% year on year to ¥1.54bn, reflecting lower earnings and negative other comprehensive income movements..

Key concerns include Likelihood: high; impact: high — achieving full-year operating-income guidance requires a Q4 margin recovery because Q3 progress is only 64.4%, 10.6 percentage points below the normal 75% pace., Likelihood: high; impact: medium — the DSO and cash conversion cycle alerts require evidence of normalization through receivable collection., Likelihood: medium; impact: high — continued SG&A growth above revenue growth would extend negative operating leverage and keep ROE below management-quality return levels., Likelihood: medium; impact: medium — the smaller Medical-related segment may remain a drag if its revenue expansion does not restore profitability..

Investment Implications

Key takeaways include Sales momentum is intact, with 8.1% consolidated revenue growth and growth in both segments., Profitability has weakened materially: operating income fell 14.6% and operating margin compressed about 330bp to 12.4%., The Water Healthcare segment remains the core business and the main determinant of any earnings recovery., Liquidity and solvency are strong, with a 312.9% current ratio, ¥13.93bn in cash, 4.1% debt/capital and 582.82x interest coverage., Receivable collection and cash conversion are the most important operating-quality issues, as indicated by 104 DSO days and a 149-day annualized cash conversion cycle., The forecast dividend payout ratio of approximately 42.7% appears sustainable on forecast earnings and current balance-sheet capacity..

Metrics to watch include Water Healthcare segment margin and SG&A-to-sales trend, Medical-related segment profit recovery, Q4 operating income versus the approximately ¥1.26bn required to achieve full-year guidance, Annualized DSO of 104 days and annualized cash conversion cycle of 149 days, Trade receivable growth relative to revenue growth, Investment securities balance and treasury-stock movements, Achievement of the ¥130 per share full-year dividend forecast.

Regarding relative positioning, The company combines above-average balance-sheet conservatism and a high gross-margin profile with currently weakening operating leverage. Its 12.4% operating margin remains within the stated good range, but its annualized 8.4% ROE is below the 10-15% good-return benchmark. Low goodwill exposure and minimal financial leverage distinguish its risk profile from acquisition-heavy or debt-funded peers, while elevated receivable days and cash conversion are the main areas where operating efficiency is weaker than manufacturing benchmarks.